Our core competence is cell-based high-throughput technologies for ex vivo and in vitro cancer research. We offer comprehensive pre-clinical drug discovery services from target discovery to target validation and beyond. The proprietary MISB cancer cell line collection is among the largest pan-cancer cell line collections in the world covering 70+ different solid tumor types allowing comprehensive pan-cancer studies and detailed indication specific discovery and biomarker programs.